Gain-of-function human <i>STAT1</i> mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis

Luyan Liu(Inserm), Satoshi Okada(Rockefeller University), Xiao‐Fei Kong(Rockefeller University), Alexandra Y. Kreins(Rockefeller University), Sophie Cypowyj(Rockefeller University), Avinash Abhyankar(Rockefeller University), Julie Toubiana(Délégation Paris 5), Yuval Itan(Rockefeller University), Magali Audry(Rockefeller University), Patrick Nitschké(Délégation Paris 5), Cécile Masson(Délégation Paris 5), Beáta Tóth(University of Debrecen), Jérome Flatot(Inserm), Mélanie Migaud(Inserm), Maya Chrabieh(Inserm), Tatiana Kochetkov(Rockefeller University), Alexandre Bolze(Inserm), A. Borghesi(Inserm), A. Toulon(Délégation Paris 5), Julia Hiller(Helmholtz Zentrum München), Stefanie Eyerich(Helmholtz Zentrum München), Kilian Eyerich(Helmholtz Zentrum München), Vera Gulácsy(University of Debrecen), Л.И. Чернышова(Shupyk National Healthcare University of Ukraine), Chernyshov Vp, Анастасія Бондаренко(Shupyk National Healthcare University of Ukraine), Rosa María Cortés Grimaldo, Lizbeth Blancas‐Galicia, Ileana María Madrigal Beas, Joachim Roesler(University Hospital Carl Gustav Carus), K. Magdorf(Charité - Universitätsmedizin Berlin), Dan Engelhard(Hadassah Academic College), C. Thumerelle(Hôpital Jeanne de Flandre), Pierre‐Régis Burgel(Hôpital Cochin), Miriam Hoernes(University of Zurich), Barbara Drexel(University of Zurich), Reinhard Seger(University of Zurich), Theresia Kusuma(Ludwig-Maximilians-Universität München), Annette Jansson(Ludwig-Maximilians-Universität München), Julie Sawalle‐Belohradsky(Ludwig-Maximilians-Universität München), Bernd H. Belohradsky(Ludwig-Maximilians-Universität München), Emmanuelle Jouanguy(Inserm), Jacinta Bustamante(Inserm), Mélanie Bué(Centre Hospitalier Régional Universitaire de Brest), Nathan Karin, Gizi Wildbaum, Christine Bodemer(University of Debrecen), Olivier Lortholary(University of Debrecen), Alain Fischer(University of Debrecen), Stéphane Blanche(University of Debrecen), Saleh Al‐Muhsen, Janine Reichenbach(University of Zurich), Masao Kobayashi(Hiroshima University), Francisco Espinosa‐Rosales, Carlos Torres Lozano, Sara Şebnem Kılıç(Bursa Uludağ Üni̇versi̇tesi̇), Matías Oleastro(Garrahan Hospital), Amos Etzioni, Claudia Traidl‐Hoffmann(Helmholtz Zentrum München), Ellen D. Renner(Ludwig-Maximilians-Universität München), Laurent Abel(Inserm), Capucine Pïcard(Délégation Paris 5), László Maródi(University of Debrecen), Stéphanie Boisson‐Dupuis(Inserm), Anne Puel(Inserm), Jean‐Laurent Casanova(Délégation Paris 5)
The Journal of Experimental Medicine
July 4, 2011
Cited by 797Open Access
Full Text

Abstract

Chronic mucocutaneous candidiasis disease (CMCD) may be caused by autosomal dominant (AD) IL-17F deficiency or autosomal recessive (AR) IL-17RA deficiency. Here, using whole-exome sequencing, we identified heterozygous germline mutations in STAT1 in 47 patients from 20 kindreds with AD CMCD. Previously described heterozygous STAT1 mutant alleles are loss-of-function and cause AD predisposition to mycobacterial disease caused by impaired STAT1-dependent cellular responses to IFN-γ. Other loss-of-function STAT1 alleles cause AR predisposition to intracellular bacterial and viral diseases, caused by impaired STAT1-dependent responses to IFN-α/β, IFN-γ, IFN-λ, and IL-27. In contrast, the 12 AD CMCD-inducing STAT1 mutant alleles described here are gain-of-function and increase STAT1-dependent cellular responses to these cytokines, and to cytokines that predominantly activate STAT3, such as IL-6 and IL-21. All of these mutations affect the coiled-coil domain and impair the nuclear dephosphorylation of activated STAT1, accounting for their gain-of-function and dominance. Stronger cellular responses to the STAT1-dependent IL-17 inhibitors IFN-α/β, IFN-γ, and IL-27, and stronger STAT1 activation in response to the STAT3-dependent IL-17 inducers IL-6 and IL-21, hinder the development of T cells producing IL-17A, IL-17F, and IL-22. Gain-of-function STAT1 alleles therefore cause AD CMCD by impairing IL-17 immunity.


Related Papers